Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Savara Inc.

SVRA

Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Last trade $4.44
Day change -$0.03 (-0.67%)
Day range $4.36 – $5.01
Volume 2,333,427
Market cap $985M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$986.19M
Price / earnings
—
Price / book
9.14×
Price / sales
—
EV / sales
—
EV / EBITDA
-6.29×

Profitability

Earnings per share
-$0.69
Return on assets
-97.95%
Return on equity
-141.62%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.28×
Current ratio
8.55×
Quick ratio
8.55×
Cash ratio
1.79×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$130.95M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SVRA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$18.54M$18.99M$15.57M$12.53M$9.63M$10.66M$9.25M$7.85M
Research and development$24.95M$21.95M$23.4M$20.9M$20.59M$20.75M$19.16M$23.29M
Total operating expenses$43.54M$40.97M$38.99M$33.42M$30.26M$31.44M$28.44M$31.17M
Operating income-$43.54M-$40.97M-$38.99M-$33.42M-$30.26M-$31.44M-$28.44M-$31.17M
Interest expense$505K$829K$0$0$548K$921K$0$0
Income before taxes-$42.99M-$40.23M-$38.14M-$32.24M-$29.56M-$30.4M-$27.42M-$29.04M
Income taxes$0$0-$853K$0$0$0-$784K$0
Net income-$42.99M-$40.23M-$37.28M-$32.24M-$29.56M-$30.4M-$26.64M-$29.04M
Net income attributable to common shareholders-$42.99M-$40.23M-$37.28M-$32.24M-$29.56M-$30.4M-$26.64M-$29.04M
EBITDA-$43.49M-$40.94M-$38.97M-$33.43M-$30.22M-$31.41M-$28.41M-$31.14M
Basic earnings per share-$0.17-$0.16-$0.15-$0.13-$0.14-$0.14-$0.12-$0.13
Diluted earnings per share-$0.17-$0.16-$0.15-$0.13-$0.14-$0.14-$0.12-$0.13

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

Savara Announces Chief Financial and Administrative Officer Transition

Savara Inc. announced that Chief Financial and Administrative Officer Dave Lowrance is stepping down effective July 15, 2026, for health-related reasons. His responsibilities will be split, with Chief Operating Officer Robert Lutz assuming the CFO role while administrative duties are distributed among senior leadership. Lutz brings over two decades of pharmaceutical industry experience and previously served as CFO at iBio and Strongbridge Biopharma.

Benzinga

Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will participate in one-on-one meetings and a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3rd. The company's lead program, MOLBREEVI, is a recombinant human GM-CSF in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).

Benzinga

Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference

Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will participate in a fireside chat at the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference on May 19th at 10:00am ET in New York. The company's lead program, MOLBREEVI, is a recombinant human GM-CSF in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).

Benzinga

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Inc. announced it received a Day 74 Letter from the FDA indicating no Advisory Committee meeting is planned for MOLBREEVI's Biologics License Application, with a PDUFA target action date of August 22, 2026. The company has submitted a Marketing Authorization Application to the European Medicines Agency and remains on track to submit to the UK's MHRA by end of Q1 2026. MOLBREEVI, a recombinant GM-CSF treatment for autoimmune PAP, has received Fast Track and Breakthrough Therapy designations from the FDA.

Benzinga

Savara Announces Participation in 2026 Citizens Life Sciences Conference

Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company, announced that its management team will participate in a fireside chat at the 2026 Citizens Life Sciences Conference on March 11th in Miami, FL. The company is focused on rare respiratory diseases with its lead program MOLBREEVI, a recombinant human GM-CSF in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.